top of page


Advanced Accelerator Applications USA, Inc. (AAA), a Novartis company, is developing targeted radioligand therapies and precision imaging radioligands for oncology indications. We are committed to transforming patients’ lives by leading innovation in nuclear medicine. AAA has a legacy as a leader in radiopharmaceutical drugs for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) diagnostic imaging. 

For more information, please visit:
164649_AAA+Nuclear+Medicine+Infographic_Digital+v4 - 2_001.png
164649_AAA+Nuclear+Medicine+Infographic_Digital+v4 - 2_002.png

Contact a representative:

Laran L. Hyder, MHA

Associate Director, US Patient Advocacy, NET & RST


This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by LACNETS. Talk to your medical team about your individual care and treatment. 

bottom of page